Related Experiment Video
Updated: May 28, 2026

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
Published on: August 24, 2019
Development of a pharmacist collaborative care program for pulmonary arterial hypertension
Pharmacists enhance Pulmonary Arterial Hypertension (PAH) care through a collaborative program. This program improves patient education and medication adherence by integrating pharmacists into multidisciplinary teams.
Area of Science:
- Cardiology
- Pharmacology
- Patient Education
Background:
- Pulmonary Arterial Hypertension (PAH) necessitates comprehensive, multidisciplinary patient care.
- Integrating pharmacists into care teams can optimize patient education and medication management for PAH patients.
Purpose of the Study:
- To describe the implementation and structure of a Pharmacist Collaborative Care Program (PCCP) for Pulmonary Arterial Hypertension (PAH) patients.
- To highlight the educational, psychosocial, and technical interventions provided by pharmacists within the PCCP.
Main Methods:
- The PCCP involves pharmacists conducting 'educational diagnoses' and providing tailored education sessions.
- Pharmacists evaluate patient skills, offer feedback to the multidisciplinary team via reports and meetings, and conduct follow-up re-evaluations.
- The program was implemented in a PAH referral center in Grenoble, France, starting in 2007.
Main Results:
- The PCCP has become an established practice in Grenoble for managing PAH patients.
- Pharmacist interventions focus on enhancing patient understanding and self-management of PAH.
- The program facilitates improved communication and feedback loops within the multidisciplinary care team.
Conclusions:
- The Pharmacist Collaborative Care Program (PCCP) demonstrates a successful model for integrating pharmacists into PAH multidisciplinary care.
- This established practice can serve as a template for future pharmacist-led patient education initiatives in France and potentially other regions.
- Pharmacist involvement is crucial for improving educational and medication adherence outcomes in complex chronic diseases like PAH.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Peripheral Artery Disease III: Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...